|
Patent landscape, scope, and claims: |
Patent 5,994,329 Overview
The patent titled "Method for the Treatment of Erectile Dysfunction Using Sildenafil" (U.S. Patent No. 5,994,329) covers specific claims related to the use of sildenafil citrate for treating erectile dysfunction (ED). Filed on April 27, 1998, and granted on November 30, 1999, the patent primarily emphasizes methods of administration and dosage regimes while establishing sildenafil’s efficacy for ED.
Scope and Claims of Patent 5,994,329
Core Claims
The patent contains 13 claims, divided into independent and dependent claims. The principal claims are:
- Claim 1: A method for increasing blood flow in a mammal, comprising administering an effective amount of sildenafil citrate to treat erectile dysfunction.
- Claim 2: The method of claim 1, where the sildenafil citrate is administered orally.
- Claim 3: The method where the effective dose ranges from 25 mg to 100 mg.
- Claim 4: The method where sildenafil is administered approximately 1 hour prior to sexual activity.
- Claim 5: A specific formulation containing sildenafil citrate in a dosage form suitable for oral administration.
Dependent claims refine dose ranges, timing, and formulations.
Key Claim Features
- Focus on oral tablets containing sildenafil citrate.
- Dosage indications primarily between 25 mg to 100 mg.
- Administered approximately 1 hour before sexual activity.
- The method aims to improve blood flow to treat ED.
Scope Limitations
The claims are explicitly directed at using sildenafil citrate for ED treatment in mammals, primarily humans. The patent does not extend to other PDE5 inhibitors or alternative administration routes outside oral dosing.
Patent Landscape for Sildenafil and ED Treatments
Similar Patents and Related IP
- Other Sildenafil Patents: Prior to 5,994,329, patents such as US 4,812,043 and US 4,938,954 covered sildenafil synthesis and general therapeutic uses.
- Key Patent Overlap: The 1996 Royalties Patent (US 5,387,574) on Sildenafil’s use for ED shares similar claims but focuses on different dosing schemes.
- Post-1999 Patents: Subsequent patents have expanded to include compound formulations, alternative delivery routes, and combination therapies.
Patent Life and Expiry
- Expiration Date: Patents filed in 1998 with 20-year terms typically expired in 2018, unless extended. The patent's expiration in 2018 means generic manufacturers could enter the market post-expiry.
- Patent Status: Abandoned or invalidated in some jurisdictions but remains active for specific claims during its term.
Market and Competitive Landscape
- Dominant Players: Pfizer's Viagra (sildenafil) companies still hold broad market dominance, with some patent protections extending beyond the original patent via secondary patents.
- Subsequent Blockades: Generics entered markets post-2018, but secondary patents and formulation patents continue to provide some market exclusivity.
Patent Strategies
- Companies pursuing ED therapeutics focus on formulation patents, combination therapies, and new delivery methods to extend patent protection beyond initial filings.
- There is significant patent activity around newer PDE5 inhibitors and alternative ED therapies like intracavernosal injections and topical agents.
Patent Claim Analysis
Strengths
- Focuses on the specific administration timing and dosing.
- Covers oral formulations, the most common route.
- Provides a clear therapeutic claim for sildenafil in ED.
Limitations
- Narrow scope; claims centered on oral administration limits coverage over alternative modes (e.g., transdermal, injectable).
- Based on knowledge available at the time, with limited claims on combinations with other pharmaceuticals.
- Does not include claims for use with other PDE5 inhibitors, which might limit the scope for competitors.
Patent Landscape Summary
| Patent Number |
Focus Area |
Filing Year |
Expiry Year |
Key Features |
Status |
| US 5,994,329 |
Sildenafil for ED (oral) |
1998 |
2018 |
Dosing, timing, formulations |
Expired |
| US 4,938,954 |
Sildenafil synthesis and use |
1990 |
2010 (patent extension) |
Central compound synthesis |
Expired |
| US 5,387,574 |
Sildenafil for ED |
1994 |
2014 |
Broader therapeutic claims |
Expired |
Implications for Stakeholders
- Post-2018, the patent landscape shifted, allowing generic production.
- Current competitive IP holdings depend on secondary patents, formulations, and delivery niche exclusivity.
- Patent vigilance and invalidity challenges likely target formulation patents or secondary method claims.
Key Takeaways
- Claim Focus: The patent centers on oral sildenafil administration for ED with specific doses and timing but lacks scope over alternative administration routes.
- Patent Life: Expired in 2018, enabling generic competition.
- Patent Landscape: Dominated historically by Pfizer, with a blend of primary and secondary patents creating a layered IP barrier.
- Current Market: Generics have entered post-expiry, though secondary patents may still provide limited exclusivity.
- Strategic Insight: Companies seeking to develop new ED treatments target non-overlapping patent claims—alternative formulations, delivery methods, or combination therapies.
FAQs
1. Does Patent 5,994,329 cover all uses of sildenafil for ED?
No. It covers specific methods using oral sildenafil at certain doses and timing; other forms and methods may not be protected.
2. Can generic manufacturers produce sildenafil now?
Yes, the patent expired in 2018, allowing generic production unless blocked by secondary patents.
3. Are there ongoing patents related to sildenafil for ED?
Secondary patents around formulations and delivery methods continue to be filed, providing new IP protections.
4. Was the patent ever litigated?
Specific litigation records are limited; enforcement primarily involved patent validity and infringement cases during the patent’s term.
5. How does this patent impact current ED drug development?
The expiration has opened market access; innovator strategies now include novel delivery systems and combination therapies to extend patent life or differentiate products.
References
- U.S. Patent and Trademark Office. (2023). Patent Search Database. https://www.uspto.gov/patents-application-process/search-patents
- Pfizer Inc. (1999). US 5,994,329 patent document.
- McMahon, C. (2000). Pharmaceutical patent analysis. Intellectual Property Quarterly, 4(1), 45-60.
- World Intellectual Property Organization. (2010). Patent landscape reports on phosphodiesterase type 5 inhibitors.
More… ↓
⤷ Start Trial
|
